Results 161 to 170 of about 1,213,487 (359)

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Clinicopathologic significance of heat shock protein 60 as a survival predictor in breast carcinoma

Frontiers in Oncology
BackgroundWhile Heat Shock Protein 60 (HSP60) has been linked to human tumor, its clinic significance specifically in breast carcinoma is unclear. This investigation aims to retrospectively evaluate how HSP60 protein levels relate to survival outcomes ...
Qing Wang, Shengzhou Chen, Zhihong Wu, Jungang Ni   +3 more
doaj   +1 more source

Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy [PDF]

, 2007
Alessandro Sciarra, Gentile Vincenzo, Autran Gomez Ana Maria, Stefano Salciccia, Alessandro Gentilucci, Salvatore Monti, Vincenzo Toscano, Di Silverio Franco   +7 more
openalex   +1 more source

Improved estimation of overall survival and progression-free survival for state transition modeling

Journal of Comparative Effectiveness Research
Aim: National Institute for Health and Care Excellence guidance (Technical Support Document 19) highlights a key challenge of state transition models (STMs) being their difficulty in achieving a satisfactory fit to the observed within-trial endpoints.
Peter C Wigfield, Bart Heeg, Mario Ouwens   +2 more
openaire   +3 more sources

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Extended Survival and Prognostic Factors in Endometrial Cancer: A Multivariate Cox Regression Analysis

Clinical and Experimental Obstetrics & Gynecology
Background: Endometrial cancer (EC) is the third most prevalent neoplasm among women in Spain and the most frequent malignancy of the female genital tract. The primary risk factors are associated with increased estrogen levels.
Irene Valencia Téllez, Laura De Pablo Zamora, María Castillo Lara, Claudia Vivas Flores, Carlos Vega Reina, Juan Jesús Fernández Alba   +5 more
doaj   +1 more source

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab [PDF]

, 2007
Salvatore Siena, Marc Peeters, Eric Van Cutsem, Yves Humblet, Pierfranco Conté, Emilio Bajetta, Danila Comandini, G. Bodoky, Guy van Hazel, Tomáš Šálek, Michael Wolf, Giovanna Devercelli, Michael Woolley, Rg Amado   +13 more
openalex   +1 more source

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study [PDF]

, 2017
We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive
Amonkar, M. M., Casey, M., Demidov, L. V., Dummer, R., Garbe, C., Grotzinger, K., Hassel, J. C., Lefeuvre-Plesse, C., Milhem, M., Mohr, P., Patel, K., Robert, C., Rutkowski, P., Rutten, A., Schadendorf, D., Sherman, L., Steven, N., Trefzer, U., Ullenhag, G., Wolter, P., Wu, F. S.   +20 more
core  

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

The Influence of Handling Censored Data on Estimating Progression-free Survival in Cancer Clinical Trials (JCOG9913-A)

, 2002
Miyuki Niimi
openalex   +1 more source